Upcoming Events
Coming soon.
WCTC4 Steering Committee:
Gregory W. Randolph, MD
Bryan McIver, MD
Jeremy Freeman, MD
Ian J. Witterick, MD
Ashok R. Shaha, MD
Jatin P. Shah, MD
Michael Tuttle, MD
EP146 – Our experience of Total Thyroidectomy in differentiated thyroid cancer – Is radioiodine ablation necessary postoperatively?
-
- Schlumberger MJ. Medical progress: papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297-306
- Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G,Gerstein HC. A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J ClinEndocrinolMetab 2004;89:3668-3676
- Rosario PW, Borges MA, Valadao MM, Vasconcelos FP, Rezende LL, Padrao EL, et al. Is adjuvant therapy useful in patients with papillary carcinoma smaller than 2 cm? Thyroid. 2007;17:1225-8
- Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-214
- Rosario PW, Ward LS, Carvalho GA, Graf H, Maciel RM, Maciel LM, et al. Thyroid nodules and differentiated thyroid cancer: update on the Brazilian consensus.Arq Bras EndocrinolMetabol. 2013;57:240-64
- Singer PA, Cooper DS, Daniels GH, Ladenson PW, Greenspan FS, Levy EG, Braverman LE, Clark OH, McDougall IR, Ain KV, Dorfman SG. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. Arch Intern Med 1996;156:2165-2172
- Rosario PW, Mourao GF. Is 131I ablation necessary for patients with low-risk papillary thyroid carcinoma and slightly elevated thyroglobulin after thyroidectomy? Arch EndocrinolMetab 2016;60/1:5-8
- Hackshaw A, Harmer C, Mallick U, Haq M, Franklyn JA. Review: 131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review. The Journal of Clinical Endocrinology & Metabolism 2007;92(1):28-38